Track the Remus Pharmaceuticals Limited stock price and the full management transaction log of the company, a listed issuer based in India. Shares are quoted on the IN market, under the supervision of SEBI (PIT + SAST). Operating in the Health Care sector, Remus Pharmaceuticals Limited has logged 214 public disclosures. Market capitalisation: €7.4bn. The latest transaction was filed on 12 January 2026 (Purchase). Among the most active insiders: Renosen Pharmaceuticals Private Limited. All data is free.
214
Insider Decl.
n/a
Thresholds
€3m
211 ops.
Buy Volume
€33,430
3 ops.
Sell Volume
10Σ signal
Buys €3m€33,430 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,717 of 28,797 companies
49.5
score / 100
Value
51
Quality
48
FCF yld0.5%
Earn yld5.0%
EV/EBITDA12.1x
ROE·
Gross mgn13%
Net mgn4.3%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,000 shares@ ₹2,035.002.4% of flowEquity SharesSEBI:9b2ed14c3b8ea12df9bbe9aadd489562522a24ee
25 of 214 declarations
About Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is a company focused on developing innovative drugs in the healthcare and pharmaceutical sector. It is listed on the XBOM.